Compare GORO & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GORO | NEPH |
|---|---|---|
| Founded | 1998 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.3M | 60.0M |
| IPO Year | N/A | 2004 |
| Metric | GORO | NEPH |
|---|---|---|
| Price | $0.88 | $5.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $1.38 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 1.4M | 67.7K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | ★ $61,430,000.00 | $17,930,000.00 |
| Revenue This Year | $8.76 | $33.32 |
| Revenue Next Year | $85.95 | $12.27 |
| P/E Ratio | ★ N/A | $36.23 |
| Revenue Growth | N/A | ★ 32.36 |
| 52 Week Low | $0.17 | $1.39 |
| 52 Week High | $1.18 | $6.42 |
| Indicator | GORO | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 63.15 | 49.99 |
| Support Level | $0.82 | $4.80 |
| Resistance Level | $0.89 | $5.97 |
| Average True Range (ATR) | 0.06 | 0.42 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 93.41 | 42.04 |
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.